O. Reg. 172/01: GENERAL, Filed May 17, 2001 under Ontario Drug Benefit Act, R.S.O. 1990, c. O.10
ontario regulation 172/01
made under the
Ontario drug benefit act
Made: May 16, 2001
Filed: May 17, 2001
Printed in The Ontario Gazette: June 2, 2001
Amending O. Reg. 201/96
(General)
Note: Since the end of 2000, Ontario Regulation 201/96 has been amended by Ontario Regulation 16/01. Previous amendments are listed in the Table of Regulations published in The Ontario Gazette dated January 20, 2001.
1. (1) The definition of “Formulary” in subsection 1 (1) of Ontario Regulation 201/96 is revoked and the following substituted:
“Formulary” means the Ministry of Health publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 37) dated March 7, 2001, including the amendments to the publication dated June 7, 2001;
(2) Section 1 of the Regulation is amended by adding the following subsection:
(3) For the purposes of this Regulation, items 255 and 256 of Part III of the Formulary are deemed to read as follows:
255 |
5mg Tab |
|
|
4.5900 |
|
02232043 |
Aricept |
PFI |
4.5900 |
256 |
10mg Tab |
|
|
4.5900 |
|
02232044 |
Aricept |
PFI |
4.5900 |
|
Reason for Use Code |
Clinical criteria |
|
|
|
347 |
For the initial trial for patients with mild to moderate Alzheimer’s disease (Mini-Mental State Exam [MMSE] 10-26), patients will be reimbursed for a period of up to three months after which continued treatment must be reassessed.
|
||
|
348 |
For continuation of therapy, further reimbursement will be made available to those patients whose disease has not progressed or deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26. |
2. (1) Subsection 1 (1) comes into force on June 7, 2001.
(2) Subsection 1 (2) comes into force on June 1, 2001.